$KYTX

Kyverna Therapeutics (KYTX) reported positive one-year data for miv-cel, showing durable responses and favorable safety in stiff person syndrome and generalized myasthenia gravis. The company plans to complete its BLA submission for SPS by Q4 2026 and finish Phase 3 enrollment for gMG by mid-2027. KYTX stock is up 8.63% in pre-market trading.

Kyverna Therapeutics (KYTX) shares rose 10% after reporting positive one-year data for miv-cel therapy in stiff person syndrome and generalized myasthenia gravis. The therapy showed sustained benefits and a well-tolerated safety profile. The company plans to complete a rolling BLA submission by Q4 2026.

Kyverna Therapeutics (KYTX) stock rose 8.1% pre-market after reporting positive 1-year data from its KYSA-8 trial for stiff person syndrome and encouraging long-term results from the KYSA-6 trial for generalized myasthenia gravis. The company plans to submit these results to the FDA by Q4 2026. Analysts have a 'Strong Buy' consensus with a $30.40 average price target.

Kyverna Therapeutics reported 1-year data for miv-cel, showing sustained efficacy and no high-grade safety issues in SPS and gMG trials. The company plans to submit this data to the FDA, keeping it on track for a Q4 application. Meanwhile, competitors Novartis and Bristol Myers Squibb faced safety setbacks in their autoimmune CAR-T trials.

Kyverna Therapeutics, Inc. (KYTX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis Topline durability data reinforce potential for single-dose miv-cel to fre

LEO Pharma agreed to acquire worldwide rights to Tanabe Pharma’s dersimelagon for up to $435m. The late-stage oral drug completed Phase III, with an FDA NDA filed June 2026. Thermo Fisher and KYAN Technologies will collaborate on precision oncology using patient-derived tumoroids. Biogen’s felzartamab won China NMPA approval for multiple myeloma. Expedition Therapeutics raised $115m Series B for EXPD-101 COPD Phase II.

Kyverna Therapeutics, Inc. (KYTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results FDA grants RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis (naSPMS) based on compelling clinical data, further expanding the therapy’s potenti

The article reviews CAR-T companies developing therapies for autoimmune diseases. Kyverna Therapeutics’ miv-cel (CD19) is in phase 3 for stiff person syndrome, with a rolling FDA BLA filing started in May and completion expected by year end. Cabaletta’s rese-cel (CD19) is in phase 1/2 for SLE and other indications, with June myositis results. Cartesian’s Descartes-08 (BCMA, mRNA) is in phase 3 for myasthenia gravis.

BlackRock, Inc. filed a Schedule 13G reporting a 5.1% beneficial stake in Kyverna Therapeutics (KYTX), totaling 3,103,757 shares. The filing shows sole voting power of 3,069,290 shares and sole dispositive power of 3,103,757 shares, with no shared voting or dispositive authority.

Kyverna Therapeutics, Inc. (KYTX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. 8-K 0001994702 false 0001994702 2026-07-23 2026-07-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23,